Recent Price Movement and Market Context
On the day the new low was recorded, Sanofi India’s stock fell by 1.61%, underperforming the Pharmaceuticals & Biotechnology sector by 0.47%. This decline is part of a broader trend, with the stock losing value for ten consecutive trading sessions, resulting in a cumulative return of -13.02% over this period. The current price is substantially below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish sentiment among market participants.
The broader market environment has also been challenging. The Sensex opened 494.06 points lower and traded at 76,312.94, down 0.72%, continuing a three-week losing streak that has seen the index fall by 7.85%. Several indices, including the S&P Bse Dollex 30, NIFTY IT, and S&P Bse Teck, also hit new 52-week lows on the same day, indicating widespread market weakness.
Financial Performance and Growth Trends
Sanofi India’s financial metrics have reflected a subdued growth profile over recent years. The company’s net sales have contracted at an annualised rate of -8.74% over the past five years, while operating profit has declined by -6.37% annually during the same period. These figures highlight a challenging environment for the company’s core business operations.
Quarterly results for the period ending December 2025 further underscore this trend. Profit after tax (PAT) stood at Rs.61.70 crore, down 33.4% compared to the average of the previous four quarters. Net sales for the quarter were Rs.419.80 crore, a decline of 13.1% relative to the prior four-quarter average. Operating profit before depreciation and interest (PBDIT) reached a low of Rs.90.30 crore, marking the weakest quarterly performance in recent times.
Long-Term and Relative Performance
Over the last year, Sanofi India’s stock has delivered a negative return of -35.49%, significantly underperforming the Sensex, which posted a positive return of 3.08% over the same period. The stock has also lagged behind the BSE500 index across multiple time frames, including the last three years, one year, and three months, reflecting persistent underperformance relative to the broader market.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Valuation and Dividend Yield
Despite the recent price decline, Sanofi India offers a relatively high dividend yield of 5.27% at the current price level. The company’s valuation metrics indicate a price-to-book value ratio of 10.7, which is considered very attractive when compared to its peers’ historical averages. This suggests that the stock is trading at a discount relative to its sector counterparts.
Balance Sheet and Efficiency Metrics
Sanofi India maintains a conservative capital structure, with an average debt-to-equity ratio of zero, indicating no reliance on debt financing. The company demonstrates strong management efficiency, reflected in a return on equity (ROE) of 49.40%, which is notably high within the Pharmaceuticals & Biotechnology sector. This level of ROE indicates effective utilisation of shareholder capital despite the recent downturn in earnings.
Institutional Holdings and Market Sentiment
Institutional investors hold a significant stake in Sanofi India, accounting for 26.86% of the shareholding. These investors typically possess greater analytical resources and a longer-term perspective on company fundamentals, which may influence trading patterns and stock price movements.
Technical Indicators Overview
Technical analysis presents a mixed picture for Sanofi India. On a weekly basis, the Moving Average Convergence Divergence (MACD) and Know Sure Thing (KST) indicators show mild bullish signals, while the Relative Strength Index (RSI) is bullish. However, monthly indicators including MACD, Bollinger Bands, KST, and Dow Theory suggest bearish momentum. Daily moving averages remain bearish, and the On-Balance Volume (OBV) indicator is negative on both weekly and monthly charts. This combination of signals reflects ongoing pressure on the stock price with intermittent signs of potential short-term support.
Sanofi India Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Metrics
Sanofi India’s current market capitalisation grade stands at 3, with a Mojo Score of 38.0 and a Mojo Grade of Sell, downgraded from Hold on 25 Feb 2026. The stock’s 52-week high was Rs.6717.50, illustrating the extent of the recent decline. The company’s performance over the past year has been subdued, with profits falling by 6.1% alongside the stock’s negative return of 35.49%.
Overall, the stock’s recent fall to a 52-week low reflects a combination of weak financial results, extended negative price momentum, and broader market headwinds affecting the sector and indices. While the company maintains strong management efficiency and a conservative balance sheet, these factors have not yet translated into positive price action in the current market environment.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
